- Home
- / Alector
Alector
Stock Price
$5.1
2024-10-29
Market Capitalization
$495.3 M
2024-10-29
Revenue
$21 M
FY, 2025
Alector Summary
Company Summary
- Overview
- Alector is a biopharmaceutical company that provides therapies for the treatment of neurodegenerative diseases. It offers latozinemab (also referred to as AL001), AL002, and AL101 product candidates. The company also develops preclinical and research pipelines, as well as blood brain barrier technology.
- Type
- Public
- Status
- Active
- Founded
- 2013
- HQ
- San Francisco, CA, US | view all locations
- Website
- https://alector.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Sara Kenkare-Mitra, President and Head of Research and Development
Gary Romano, Chief Medical Officer
Marc Grasso, Chief Financial Officer
Operating MetricsView all
Patent Applications
380
26.7%
FY, 2021
Patent Families
50
25.0%
FY, 2021
Product Candidates
4
FY, 2019
LocationsView all
1 location detected
San Francisco, CA HQ
United States
131 Oyster Point Blvd #600
Alector Financials
Summary Financials
- Revenue (Q1, 2026)
- $1.0M
- Net income (Q1, 2026)
- ($22.9M)
- Cash (Q1, 2026)
- $77.0M
- EBIT (Q1, 2026)
- ($24.9M)
- Enterprise value
- $452.9M